Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 6/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | STAT1 | P42224 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.42 |
| ▸ | TUBB | P07437 | 2/20 | 0.42 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.42 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.42 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.42 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.42 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.42 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.42 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.42 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.42 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5752420 | 0.90 | ABCG2 (0.56) | ABCG2MAPTMAPK1LMNASMN1; SMN2 | |
| SCHEMBL5752197 | 0.85 | CA9 (0.45) | ABCG2MAPTMAPK1LMNASMN1; SMN2 | |
| SCHEMBL5754227 | 0.84 | CYP1A2 (0.49) | ABCG2MAPTMAPK1LMNASMN1; SMN2 | |
| SCHEMBL5753588 | 0.81 | PIK3CA (0.49) | MAPTMAPK1SMN1; SMN2CYP1A2CYP3A4 | |
| SCHEMBL5749673 | 0.75 | MAPK1 (0.47) | ABCG2MAPTMAPK1LMNASMN1; SMN2 | |
| SCHEMBL5754023 | 0.72 | MAPK1 (0.55) | ABCG2MAPK1CYP1A2CYP3A4CYP2C19 | |
| SCHEMBL21490327 | 0.72 | MAPT (0.67) | MAPTMAPK1LMNASMN1; SMN2NPC1 | |
| SCHEMBL12297372 | 0.71 | CSNK2A1 (0.69) | MAPTSMN1; SMN2NPC1HTTRAB9A | |
| SCHEMBL5752653 | 0.70 | MEN1 (0.56) | MAPK1LMNASMN1; SMN2NPC1RAB9A | |
| SCHEMBL5753106 | 0.70 | KDR (0.41) | MAPTMAPK1NPC1RAB9ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1651619-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMIN ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | claimed |
| WO-2005009977-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMINA ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | claimed |
| US-20060229308-A1 | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands | NEUROGEN CORPORATION (US) | 2006-10-12 | — | — | US | disclosed |
| EP-1651619-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMIN ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2006-05-03 | — | — | EP | disclosed |
| WO-2005009977-A1 | SUBSTITUTED PYRIMIDIN-4-YLAMINA ANALOGUES AS VANILLOID RECEPTOR LIGANDS | NEUROGEN CORPORATION (US) | 2005-02-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060229308-A1 | Substituted pyrirmidin-4-ylamine analogues as vanilloid receptor ligands | TRPV1, GPR17, TRPV2 | ABCG2 812/4885MAPT 4343/4885MAPK1 3408/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.